How biomarkers can predict patients’ responses to ICI treatments – CRI

CRI (Cancer Research Institute) shared a post on LinkedIn:

”Led by CRI Scientific Advisory Council member Padmanee Sharma of MD Anderson Cancer Center, findings from the AMADEUS clinical trial shed light on how biomarkers can predict patients’ responses to immune checkpoint inhibitor treatments including nivolumab and ipilimumab. Understand the key discoveries from this study, in our new blog post.”

Read further.
Source: CRI/LinkedIn

Padmanee Sharma, M.D., Ph.D., is the Director of Scientific Programs at the James P. Allison Institute and the inaugural Scientific Director of the Immunotherapy Platform at MD Anderson Cancer Center. She holds professorships in Genitourinary Medical Oncology and Immunology and serves as the T.C. and Jeanette Hsu Endowed Chair in Cell Biology. Dr. Sharma also co-directs the Parker Institute for Cancer Immunotherapy. She pioneered the first neoadjuvant clinical trial with immune checkpoint therapy, contributing to the FDA approval of these therapies for bladder cancer and renal cell carcinoma.